Evidence map›Paper›PMID 39096016›Full record

ArticleHead & neck2025

The association between skeletal muscle mass and sensorineural hearing loss upon cisplatin-based chemoradiotherapy in patients with head and neck squamous cell carcinoma.

Anouk W M A Schaeffers, Anouk V M Burger, Charlotte W Duinkerken, Klaske E van Sluis, Jan Paul de Boer, Lisette van der Molen, Alex E Hoetink, Abrahim Al-Mamgani, Katarzyna Jóźwiak, Lot A Devriese and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Head & neck, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Anouk W M A SchaeffersDepartment of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0002-7952-8734
Anouk V M BurgerDepartment of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Charlotte W DuinkerkenDepartment of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Klaske E van SluisDepartment of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID 0000-0002-9288-5402
Jan Paul de BoerDepartment of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Lisette van der MolenDepartment of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Alex E HoetinkDepartment of Otorhinolaryngology - Head and Neck Surgery, University Medical Center Utrecht, UMC Brain Centre, Utrecht, the Netherlands.
Abrahim Al-MamganiDepartment of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Katarzyna JóźwiakInstitute of Biostatistics and Registry Research, Brandenburg Medical School Theodor Fontane, Neuruppin, Germany.
Lot A DevrieseDepartment of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
Remco de BreeDepartment of Head and Neck Surgical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.ORCID 0000-0001-7128-5814
Charlotte L ZuurDepartment of Head and Neck Surgery and Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with head and neck squamous cell carcinoma (HNSCC) treated with cisplatin-based chemoradiotherapy (CRT) frequently experience irreversible sensorineural hearing loss (SNHL). Patients with low lumbar skeletal muscle index (LSMI) may experience higher serum peak dosages of cisplatin. This study investigated whether pre-treatment low LSMI is associated with increased SNHL upon cisplatin-based CRT. MATERIALS AND

methodsLSMI was assessed using routine pre-treatment CT scans. Pure tone audiometry was performed at baseline and at follow-up to assess treatment-related SNHL. Linear mixed models were used to reveal a potential association between the continuous variable LSMI and SNHL.

resultsThis retrospective cohort study included 81 patients and found a significant association between low LSMI and increased treatment-related SNHL at pure tone frequencies vital for the perception of speech (averaged of 1, 2, and 4 kHz) (p = 0.048).

conclusionsHNSCC patients with low LSMI suffer increased treatment-related SNHL upon cisplatin-based CRT.

Indexed as

ChemoradiotherapyCisplatinHead and Neck NeoplasmsHearing Loss, SensorineuralSquamous Cell Carcinoma of Head and NeckAdultAgedAntineoplastic AgentsAudiometry, Pure-ToneCohort StudiesFemaleHumansMaleMiddle AgedMuscle, SkeletalRetrospective StudiesAntineoplastic AgentsCisplatinchemoradiotherapycisplatinhead and neckhearing lossototoxicityskeletal muscle mass

Identifiers

PMID39096016
PMCPMC11635742

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.